Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance
1997

Bcl-2/Bax Ratios in Chronic Lymphocytic Leukaemia

Sample size: 22 publication Evidence: moderate

Author Information

Author(s): C Pepper, T Hoy, DP Bentley

Primary Institution: Department of Haematology, Llandough Hospital; Department of Haematology, University of Wales College of Medicine

Hypothesis

The study aims to examine the relationship between Bcl-2/Bax ratios, clinical resistance, and in vitro apoptosis in patients with B-CLL.

Conclusion

Higher Bcl-2/Bax ratios are associated with clinical resistance to chemotherapy in B-CLL patients.

Supporting Evidence

  • Bcl-2 and Bax protein levels were significantly altered in B-CLL patients compared to normal controls.
  • Elevated Bcl-2/Bax ratios were observed in treated patients who were clinically unresponsive to chemotherapy.
  • The study found a correlation between Bcl-2/Bax ratios and ID50 values for chlorambucil treatment.

Takeaway

This study found that the balance between two proteins, Bcl-2 and Bax, can help predict how well patients with a type of blood cancer respond to treatment.

Methodology

The study involved analyzing Bcl-2 and Bax protein levels in peripheral blood lymphocytes from B-CLL patients using flow cytometry and assessing their response to chlorambucil treatment.

Limitations

The study does not clarify whether the observed drug resistance is due to selection of a resistant population or induction of drug resistance.

Participant Demographics

Patients with B-cell chronic lymphocytic leukaemia, including treated and untreated individuals.

Statistical Information

P-Value

0.0001

Statistical Significance

p=0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication